Newsroom

Press Releases

See All

05/05/2021

Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
05/04/2021

Sarepta Therapeutics to Present at Upcoming Investor Conferences
05/03/2021

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

News Features

01/13/2021

How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
12/18/2020

Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
10/14/2020

Welcome to GT‐FAQ!
09/29/2020

Expanding Access to Newborn Screening for Those with Rare Diseases
09/14/2020

Room to Grow – From Sarepta Intern to Making Impact on the Pipeline
06/12/2020

Patiently Waiting

Media Library

View All Media Library

Sarepta Corporate Logo

Sarepta Building Exterior thumbnail

Sarepta Building Exterior

LGMD Fact sheet thumbnail

LGMD Fact Sheet

NSAA Fact Sheet Thumbnail

NSAA Fact Sheet

Press Contact

Tracy Sorrentino
Senior Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052